HUMAN FAECAL MATTER

Hepatocellular Carcinoma (HCC)

Wang Xinother_biologicalPhase 2Active

CCC

51/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 73/ 100

Competitive context

47 Active assets in the Hepatocellular Carcinoma (HCC) cohort.

Asset / Sponsor	Phase	Rating
Enzalutamide Exelixis	Phase 3	B
Icaritin Northern Jiangsu People's Hospital	Phase 3	B
Pexastimogene Devacirepvec Transgene	Phase 3	B
Biejia-Ruangan Compound Nanfang Hospital, Southern Medical University	Phase 4	B
hlx13 Shanghai Henlius Biotech	Phase 3	B

View all 50 →

Same molecule, other indications

HUMAN FAECAL MATTER is also rated in:

cirrhosis of liverDormant

BB

Indicative ·

66 / 100

hepatic encephalopathyDormant

B

Indicative ·

61 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.